Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic Myelogenous Leukemia

NCT03576547 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03576547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03576547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic Myelogenous Leukemia
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Terminated
Start date
June 26, 2018
Completion date
June 19, 2024
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blast phase chronic myelogenous leukemia, bcr-abl1 positive, philadelphia chromosome positive, recurrent acute lymphoblastic leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, refractory acute lymphoblastic leukemia, refractory chronic myelogenous leukemia, bcr-abl1 positive, t(9;22)